These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 15274165)

  • 1. Clinical outcomes of patent foramen ovale closure for paradoxical emboli without echocardiographic guidance.
    Varma C; Benson LN; Warr MR; Yeo E; Yip J; Jaigobin CS; Webb G; McLaughlin PR
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):519-25. PubMed ID: 15274165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices.
    Bissessor N; Wong AW; Hourigan LA; Jayasinghe RS; Scalia GS; Burstow DJ; Griffiths LR; Savage M; Walters DL
    Cardiovasc Revasc Med; 2011; 12(3):164-169. PubMed ID: 21640934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size.
    Wahl A; Tai T; Praz F; Schwerzmann M; Seiler C; Nedeltchev K; Windecker S; Mattle HP; Meier B
    JACC Cardiovasc Interv; 2009 Feb; 2(2):116-23. PubMed ID: 19463412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
    Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
    Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism.
    Spies C; Khandelwal A; Timmemanns I; Kavinsky CJ; Schräder R; Hijazi ZM
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):966-70. PubMed ID: 18942060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement.
    Hung J; Landzberg MJ; Jenkins KJ; King ME; Lock JE; Palacios IF; Lang P
    J Am Coll Cardiol; 2000 Apr; 35(5):1311-6. PubMed ID: 10758974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
    Fischer D; Haentjes J; Klein G; Schieffer B; Drexler H; Meyer GP; Schaefer A
    J Interv Cardiol; 2011 Feb; 24(1):85-91. PubMed ID: 20735710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous patent foramen ovale closure using Helex and Amplatzer devices without intraprocedural echocardiographic guidance.
    Siddiqui IF; Michaels AD
    J Interv Cardiol; 2011 Jun; 24(3):271-7. PubMed ID: 21114532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism.
    Khositseth A; Cabalka AK; Sweeney JP; Fortuin FD; Reeder GS; Connolly HM; Hagler DJ
    Mayo Clin Proc; 2004 Jan; 79(1):35-41. PubMed ID: 14708946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events.
    Balbi M; Casalino L; Gnecco G; Bezante GP; Pongiglione G; Marasini M; Del Sette M; Barsotti A
    Am Heart J; 2008 Aug; 156(2):356-60. PubMed ID: 18657668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent venous valves correlate with increased shunt and multiple preceding cryptogenic embolic events in patients with patent foramen ovale: an intracardiac echocardiographic study.
    Rigatelli G; Dell'avvocata F; Braggion G; Giordan M; Chinaglia M; Cardaioli P
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):973-6. PubMed ID: 19021284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
    Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent foramen ovale closure devices.
    Shafi NA; McKay RG; Kiernan FJ; Silverman IE; Ahlquist M; Silverman DI
    Int J Cardiol; 2009 Nov; 137(3):314-6. PubMed ID: 19616327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventional closure of patent foramen ovale with Nit-occlud® device in prevention of recurrent neurologic events-Long-term results.
    Araszkiewicz A; Sławek S; Trojnarska O; Lesiak M; Grygier M
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):159-164. PubMed ID: 29068141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual shunting after percutaneous PFO closure: how to manage and how to close.
    Butera G; Sarabia JF; Saracino A; Chessa M; Piazza L; Carminati M
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):950-8. PubMed ID: 23804551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
    Luermans JG; Post MC; Schräder R; Sluysmans T; Vydt T; Vermeersch P; Chessa M; Onorato E; Goy JJ; Budts WI
    Catheter Cardiovasc Interv; 2008 May; 71(6):822-8. PubMed ID: 18324695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack.
    Steinberg DH; Bertog SC; Momberger J; Franke J; Hofmann I; Renkhoff K; Joy S; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1262-7. PubMed ID: 24948394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter PFO closure with GORE(®) septal occluder: early and mid-term clinical results.
    Butera G; Saracino A; Danna P; Sganzerla P; Chessa M; Carminati M
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):944-9. PubMed ID: 23897659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.